Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Crystal Arthritis
•
Primary Care
When would you recommend uric acid-lowering therapy for a patient with asymptomatic hyperuricemia without comorbidities but with family history of gout?
Related Questions
Do you prefer allopurinol or febuxostat for patients with chronic kidney disease who are receiving treatment for asymptomatic hyperuricemia?
Do you avoid hyaluronic acid injections in patients with chondrocalcinosis on imaging?
If a patient who has tolerated allopurinol for a prolonged period of time is subsequently found to be positive for the HLA-B*58:01 gene, how would you manage urate-lowering therapy thereafter?
Do you prefer using losartan in your patients with hypertension and gout due to its uricosuric effects?
Do you still consider the use of pegloticase in someone with substantial tophaceous burden despite optimal uric acid levels?
Would you use febuxostat for an African-American patient with gout and previous cardiovascular events (stroke, MI) who tested positive for HLA-B*5801?
How do you counsel patients with autoimmune disease who are considering platelet-rich plasma injections for a musculoskeletal condition unrelated to their autoimmune disease?
Are you comfortable trying a different JAK inhibitor in patients with prior JAK inhibitor allergy?
How do you approach management of osteoporosis in patients post lung transplant?
Do you recommend adjusted adult cancer screening for patients who have been on long term biologics and/or tsDMARDs since childhood?
